Montezyd 4/Montezyd 5/Montezyd 10

Montelukast sodium, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor. Montelukast sodium is described chemically as [R-(E)]-1-[[[1-[3-[2-(7-chloro-2quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1 methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid, monosodium salt. The empirical formula is C₃₅H₃₅ClNNaO₃S, and its molecular weight is 608.18.
Montelukast sodium is a hygroscopic, optically active, white to off-white powder. Montelukast sodium is freely soluble in ethanol, methanol, and water and practically insoluble in acetonitrile.
Montezyd 4/Montezyd 5: Each chewable tablet contains: Montelukast (as Sodium) (Montezyd 4) 4 mg.
Montelukast (as Sodium) (Montezyd 5) 5 mg.
Each 4‑mg and 5‑mg chewable Montelukast tablet contains 4.2 and 5.2 mg Montelukast sodium, respectively, which are equivalent to 4 and 5 mg of Montelukast, respectively.
Montezyd 10: Each film-coated tablet contains: Montelukast (as Sodium) 10 mg.

Leukotriene Receptor Antagonist.
Pharmacology: The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type‑1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene‑mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late‑phase reactions and are associated with symptoms of allergic rhinitis. Intranasal challenge with CysLTs has been shown to increase nasal airway resistance and symptoms of nasal obstruction. Montelukast has not been assessed in intranasal challenge studies. The clinical relevance of intranasal challenge studies is unknown.
Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β‑adrenergic receptor). Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity.
Pharmacodynamics: Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics. Doses as low as 5 mg cause substantial blockage of LTD4-induced bronchoconstriction. In a placebo-controlled, crossover study (n=12), Montelukast inhibited early- and late-phase bronchoconstriction due to antigen challenge by 75% and 57%, respectively.
The effect of Montelukast on eosinophils in the peripheral blood was examined in clinical trials. In patients with asthma aged 2 years and older who received Montelukast, a decrease in mean peripheral blood eosinophil counts ranging from 9% to 15% was noted, compared with placebo, over the double-blind treatment periods. In patients with seasonal allergic rhinitis aged 15 years and older who received Montelukast, a mean increase of 0.2% in peripheral blood eosinophil counts was noted, compared with a mean increase of 12.5% in placebo-treated patients, over the double-blind treatment periods; this reflects a mean difference of 12.3% in favor of Montelukast. The relationship between these observations and the clinical benefits of Montelukast noted in the clinical trials is not known.
Pharmacokinetics: Montezyd 4/Montezyd 5: Absorption: For the 5 mg chewable tablet, the Cmax is achieved 2 hours after administration in adults in the fasted state. The mean oral bioavailability is 73%. Food does not have a clinically important influence with chronic administration.
For the 4 mg chewable tablet, Cmax is achieved 2 hours after administration in paediatric patients 2 to 5 years of age in the fasted state.
Safety and efficacy were demonstrated in clinical studies where the 4 mg chewable tablet and 5 mg chewable tablet, were administered without regard to the timing of food ingestion.
Distribution: Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of Montelukast averages 8 to 11 litres. Studies in rats with radiolabeled Montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabeled material at 24 hours post-dose were minimal in all other tissues.
Metabolism: Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of Montelukast are undetectable at steady state in adults and paediatric patients.
In vitro studies using human liver microsomes indicate that cytochrome P450 3A4 and 2C9 are involved in the metabolism of Montelukast. Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of Montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6.
Elimination: The plasma clearance of Montelukast averages 45 mL/min in healthy adults. Following an oral dose of radiolabeled Montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and <0.2% was recovered in urine. Coupled with estimates of Montelukast oral bioavailability, this indicates Montelukast and its metabolites are excreted almost exclusively via the bile.
In several studies, the mean plasma half-life of Montelukast ranged from 2.7 to 5.5 hours in healthy young adults. The pharmacokinetics of Montelukast are nearly linear for oral doses up to 50 mg. No difference in pharmacokinetics was noted between dosing in the morning or in the evening.
Montezyd 10: Absorption: Montelukast is rapidly and nearly completely absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal.
Distribution: Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of Montelukast averages 8 to 11 litres. Studies in rats with radiolabeled Montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabeled material at 24 hours post-dose were minimal in all other tissues.
Metabolism: Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of Montelukast are undetectable at steady state in adults and paediatric patients. In vitro studies using human liver microsomes indicate that cytochrome P450 3A4 and 2C9 are involved in the metabolism of Montelukast. Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of Montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6.
Elimination: The plasma clearance of Montelukast averages 45 mL/min in healthy adults. Following an oral dose of radiolabeled Montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and <0.2% was recovered in urine. Coupled with estimates of Montelukast oral bioavailability, this indicates Montelukast and its metabolites are excreted almost exclusively via the bile. In several studies, the mean plasma half-life of Montelukast ranged from 2.7 to 5.5 hours in healthy young adults. The pharmacokinetics of Montelukast are nearly linear for oral doses up to 50 mg. No difference in pharmacokinetics was noted between dosing in the morning or in the evening. During once-daily dosing with 10 mg Montelukast, there is little accumulation of the parent medicine in plasma (~14%).
Characteristics in Patients: Gender: The pharmacokinetics of Montelukast are similar in males and females.
Elderly: The pharmacokinetic profile and the oral bioavailability of a single 10 mg oral dose of Montelukast are similar in elderly and younger adults. The plasma half-life of Montelukast is slightly longer in the elderly. No dosage adjustment in the elderly is required.
Race: Pharmacokinetic differences due to race have not been studied. In clinical studies, there do not appear to be any differences in clinically important effects.
Hepatic Insufficiency: Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of Montelukast resulting in approximately 41% higher mean Montelukast area under the plasma concentration curve (AUC) following a single 10 mg dose. The elimination of Montelukast is slightly prolonged compared with that in healthy subjects (mean half-life, 7.4 hours). No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency. There are no clinical data in patients with severe hepatic insufficiency.
Renal Insufficiency: Since Montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of Montelukast were not evaluated in patients with renal insufficiency. No dosage adjustment is recommended in these patients.
Adolescents and Paediatric Patients: The plasma concentration profile of Montelukast following the 10 mg film-coated tablet is similar in adolescents ≥15 years old and young adults. The 10 mg film-coated tablet is recommended for use in patients ≥15 years old.
Pharmacokinetic studies using either the chewable tablet or film-coated tablet show that the plasma profile of the 5 mg chewable tablet in paediatric patients 6 to 14 years of age is similar to that of the 10 mg film-coated tablet in adults. In a pharmacokinetic study in paediatric patients 2 to 5 years of age, the plasma profile of the 4 mg chewable tablet was also similar to that of the 10 mg film-coated tablet in adults. The 5 mg chewable tablet should be used in paediatric patients 6 to 14 years of age and the 4 mg chewable tablet in paediatric patients 2 to 5 years of age.

Montezyd 4/Montezyd 5: Prevention of exercise‑induced bronchospasm. It is also indicated for the relief of daytime and night time symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.
Montezyd 10: It is indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and night-time symptoms and the prevention of exercise-induced bronchospasm.
It is indicated in adults and paediatric patients 2 years of age and older for the relief of daytime and night time symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.

It should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualised to suit patient needs. Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening.
General Recommendations: The therapeutic effect of Montelukast tablets on parameters of asthma control occurs within one day. Montelukast tablets may be taken with or without food. Patients should be advised to continue taking Montelukast tablets while their asthma is controlled, as well as during periods of worsening asthma.
No dosage adjustment is necessary for paediatric patients, for the elderly, for patients with renal insufficiency, or mild‑to-moderate hepatic impairment, or for patients of either gender.
Montezyd 4/Montezyd 5: Paediatric Patients 6 to 14 Years of Age with Asthma and/or Allergic Rhinitis: The dosage for paediatric patients 6 to 14 years of age is one5 mg chewable tablet daily.
Paediatric Patients 2 to 5 Years of Age with Asthma and/or Allergic Rhinitis: The dosage for paediatric patients 2 to 5 years of age is one 4 mg chewable tablet daily.
Montezyd 10: Adults 15 Years of Age and Older with Asthma and/or Allergic Rhinitis: The dosage for adults 15 years of age and older is one 10 mg tablet daily.
Therapy with Montelukast in Relation to Other Treatments for Asthma: Montelukast can be added to a patient's existing treatment regimen.
Reduction in Concomitant Therapy: Bronchodilator Treatments: It can be added to the treatment regimen of patients who are not adequately controlled on bronchodilator alone. When a clinical response is evident (usually after the first dose), the patient's bronchodilator therapy can be reduced as tolerated.
Inhaled Corticosteroids: Treatment with Montelukast provides additional clinical benefit to patients treated with inhaled corticosteroids. A reduction in the corticosteroid dose can be made as tolerated. The dose should be reduced gradually with medical supervision. In some patients, the dose of inhaled corticosteroids can be tapered off completely.
Montelukast should not be abruptly substituted for inhaled corticosteroids.
Oral Corticosteroids: Limited data suggest that Montelukast may provide additional clinical benefit in patients with oral corticosteroids.

No specific information is available on the treatment of overdosage with Montelukast tablets. In chronic asthma studies, it has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences. There have been reports of acute overdosage in postmarketing experience and clinical studies with Montelukast tablets. These include reports in adults and children with a dose as high as 1000 mg. The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of Montelukast tablets and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. It is not known whether Montelukast is dialysable by peritoneal- or haemodialysis.

Hypersensitivity to any component of this product.

The efficacy of oral Montelukast tablets for the treatment of acute asthma attacks has not been established. Therefore, oral Montelukast tablets should not be used to treat acute asthma attacks. Patients should be advised to have appropriate rescue medication available.
While the dose of concomitant inhaled corticosteroid may be reduced gradually under medical supervision, Montelukast tablets should not be abruptly substituted for inhaled or oral corticosteroids.
The reduction in systemic corticosteroid dose in patients receiving anti-asthma agents including leukotriene receptor antagonists has been followed in rare cases by the occurrence of one or more of the following: eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy sometimes diagnosed as Churg-Strauss syndrome, a systemic eosinophilic vasculitis. Although a causal relationship with leukotriene receptor antagonism has not been established, caution and appropriate clinical monitoring are recommended when systemic corticosteroid reduction is considered in patients receiving Montelukast tablets.
Renal/Hepatic Impairment: No dosage adjustment is required for patients with renal insufficiency or mild to moderate hepatic impairment.
Carcinogenicity and Mutagenicity: There were no significant results seen with Montelukast sodium in carcinogenicity or mutagenicity studies.
Use in Pregnancy & Lactation: See USE IN PREGNANCY & LACTATION section for further information.
Use in Children: Montelukast tablets have been studied in paediatric patients 2 to 14 years of age. Safety and effectiveness in paediatric patients younger than 2 years of age have not been studied. Studies have shown that Montelukast tablets do not affect the growth rate of paediatric patients.
Use in the Elderly: In clinical studies, there were no age-related differences in the efficacy or safety profiles of Montelukast tablets.
Montezyd 4/Montezyd 5: Phenylketonurics꞉ Phenylketonuric patients should be informed that the 4 mg and the 5 mg chewable tablets contain phenylalanine (a component of aspartame) 674 and 842 mcg per 4 mg and 5 mg chewable tablet, respectively.
Montezyd 10: Reproduction: In pre-clinical studies, there were no significant results in reproduction studies conducted with Montelukast sodium.
Development: In developmental toxicity studies, there were no treatment related adverse effects at doses up to 400 mg/kg/day in rats and up to 100 mg/kg/day in rabbits. Fetal exposure of Montelukast sodium in rats and rabbits does occur and significant concentrations of medicine were observed in milk of lactating rats.
Effect on Ability to Drive and use Machines: There is no evidence that Montelukast tablets affect the ability to drive and use machines.

Pregnancy: Montelukast tablets have not been studied in pregnant women. Montelukast tablets should be used during pregnancy only if clearly needed. During worldwide marketing experience, congenital limb defects have been rarely reported in the offspring of women being treated with Montelukast tablets during pregnancy. Most of these women were also taking other asthma medications during their pregnancy. A causal relationship between these events and Montelukast tablets has not been established.
Nursing Mothers: It is not known if Montelukast tablets are excreted in human milk. Because many medicines are excreted in human milk, caution should be exercised when Montelukast tablets are given to a nursing mother.

Montelukast has been generally well tolerated. Adverse effects, which usually were mild, generally did not require discontinuation of therapy. The overall incidence of adverse effects (including laboratory adverse effects) reported with Montelukast was comparable to placebo.
Montezyd 4/Montezyd 5: Paediatric Patients 6 to 14 Years of Age with Asthma: Montelukast has been evaluated in approximately 475 paediatric patients 6 to 14 years of age. The safety profile in paediatric patients is generally similar to the adult safety profile and to placebo.
In an 8‑week, placebo‑controlled clinical study, the only adverse experience reported as medicine‑related in >1% of patients treated with Montelukast and at a greater incidence than in patients treated with placebo was headache. The incidence of headache was not significantly different in the two treatment groups.
In studies evaluating the growth rate, the safety profile in these paediatric patients was consistent with the safety profile previously described for Montelukast. Cumulatively, 263 paediatric patients 6 to 14 years of age were treated with Montelukast for at least 3 months and 164 for 6 months or longer. With prolonged treatment, the adverse experience profile did not change.
Paediatric Patients 2 to 5 Years of Age with Asthma: Montelukast has been evaluated in 573 paediatric patients 2 to 5 years of age. In a 12‑week, placebo‑controlled clinical study, the only adverse experience reported as medicine‑related in >1% of patients treated with Montelukast and at a greater incidence than in patients treated with placebo was thirst. The incidence of thirst was not significantly different in the two treatment groups.
Cumulatively, 426 paediatric patients 2 to 5 years of age were treated with Montelukast for at least 3 months, 230 for 6 months or longer, and 63 patients for 12 months or longer. With prolonged treatment, the adverse experience profile did not change.
Paediatric Patients 2 to 14 Years of Age with Seasonal Allergic Rhinitis: Montelukast has been evaluated in 280 paediatric patients 2 to 14 years of age for the treatment of seasonal allergic rhinitis in a 2‑week, placebo‑controlled, clinical study. Montelukast administered once daily in the evening was generally well tolerated with a safety profile similar to that of placebo. In this study, no adverse experiences reported as drug related in ≥1% of patients treated with Montelukast and at a greater incidence than in patients treated with placebo were observed.
Montezyd 10: Adults 15 Years of Age and Older with Asthma: Montelukast has been evaluated in approximately 2600 adult patients 15 years of age and older in clinical studies. In two similarly designed, 12-week placebo-controlled clinical studies, the only adverse experiences reported as medicine-related in ≥1% of patients treated with Montelukast and at a greater incidence than in patients treated with placebo were abdominal pain and headache.
The incidences of these events were not significantly different in the two treatment groups. Cumulatively, 544 patients were treated with Montelukast for at least 6 months, 253 for one year and 21 for 2 years in clinical studies. With prolonged treatment, the adverse experience profile did not change.
Adults 15 Years of Age and Older with Seasonal Allergic Rhinitis: Montelukast has been evaluated in 2199 adult patients 15 years of age and older for the treatment of seasonal allergic rhinitis in clinical studies. Montelukast administered once daily in the morning or in the evening was generally well tolerated with a safety profile similar to that of placebo. In placebo-controlled clinical studies, no adverse experiences reported as drug related in ≥1% of patients treated with Montelukast and at a greater incidence than in patients treated with placebo were observed. In a 4-week, placebo-controlled clinical study, the safety profile was consistent with that observed in 2-week studies. The incidence of somnolence was similar to that of placebo in all studies.
Adults 15 Years of Age and Older with Perennial Allergic Rhinitis: Montelukast has been evaluated in 3235 adult and adolescent patients 15 years of age and older with perennial allergic rhinitis (defined as a history of symptoms for at least two years and positive skin tests for at least two perennial allergens) in two, 6 week, placebo -controlled, clinical studies. Montelukast administered once daily was generally well tolerated, with a safety profile consistent with that observed in patients with seasonal allergic rhinitis and similar to that of placebo. In these two studies, no adverse experiences reported as drug related in ≥1% of patients treated with Montelukast and at a greater incidence than in patients treated with placebo were observed. The incidence of somnolence was similar to that of placebo.

Montezyd 10: Montelukast tablets may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma, and in the treatment of allergic rhinitis. In medicine-interactions studies, the recommended clinical dose of Montelukast did not have clinically important effects on the pharmacokinetics of the following medicines: theophylline, prednisone, prednisolone, oral contraceptives (ethinylestradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.
Although additional specific interaction studies were not performed, Montelukast tablets were used concomitantly with a wide range of commonly prescribed medicines in clinical studies without evidence of clinical adverse interactions. These medications included thyroid hormones, sedative hypnotics, nonsteroidal anti-inflammatory agents, benzodiazepines and decongestants.
The area under the plasma concentration-time curve (AUC) for Montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. No dosage adjustment for Montelukast tablets is recommended.
In vitro studies have shown that Montelukast is an inhibitor of CYP2C8. However, data from a clinical drug-drug interaction study involving Montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolised by CYP2C8) demonstrated that Montelukast does not inhibit CYP2C8 in vivo. Therefore, Montelukast is not anticipated to alter the metabolism of drugs metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, repaglinide). Montelukast tablets may be taken with or without food. There are no data available on the use of Montelukast tablets and alcohol.

Store at temperatures not exceeding 30°C.

Antiasthmatic & COPD Preparations

R03DC03 - montelukast ; Belongs to the class of leukotriene receptor antagonists. Used in the systemic treatment of obstructive airway diseases.

Rx